Thomas Stephen J
SUNY Upstate Medical University, Institute for Global Health and Translational Sciences, Syracuse, NY, USA.
NPJ Vaccines. 2023 Apr 15;8(1):55. doi: 10.1038/s41541-023-00658-2.
Dengue is a major global public health problem requiring a safe and efficacious vaccine as the foundation of a comprehensive countermeasure strategy. Despite decades of attempts, the world has a single dengue vaccine licensed in numerous countries, but restrictions and conditions of its use have deterred uptake. Recently, clinical efficacy data has been revealed for two additional dengue vaccine candidates and the data appears encouraging. In this perspective I discuss dengue, the complexities of dengue vaccine development, early development setbacks, and how the latest data from the field may be cause for measured optimism. Finally, I provide some perspectives on evaluating dengue vaccine performance and how the pursuit of the perfect dengue vaccine may prevent advancement of vaccines which are good enough.
登革热是一个重大的全球公共卫生问题,需要一种安全有效的疫苗作为综合应对策略的基础。尽管经过了数十年的努力,但全球仅有一种登革热疫苗在众多国家获得许可,但其使用限制和条件阻碍了疫苗的推广。最近,又有两种登革热候选疫苗公布了临床疗效数据,这些数据看起来令人鼓舞。在这篇观点文章中,我将讨论登革热、登革热疫苗研发的复杂性、早期研发挫折,以及该领域的最新数据如何可能成为适度乐观的理由。最后,我提供了一些关于评估登革热疫苗性能的观点,以及追求完美的登革热疫苗可能如何阻碍足够好的疫苗的进展。